Literature DB >> 9243058

Candida inconspicua, a fluconazole-resistant pathogen in patients infected with human immunodeficiency virus.

G G Baily1, C B Moore, S M Essayag, S de Wit, J P Burnie, D W Denning.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9243058     DOI： 10.1086/516894

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  5 in total

Review 1.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

Review 2.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

3.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion.

Authors:  M A Pfaller; D J Diekema; D L Gibbs; V A Newell; D Ellis; V Tullio; A Rodloff; W Fu; T A Ling
Journal:  J Clin Microbiol       Date:  2010-02-17       Impact factor: 5.948

4.  Restriction enzyme analysis of ribosomal DNA shows that Candida inconspicua clinical isolates can be misidentified as Candida norvegensis with traditional diagnostic procedures.

Authors:  L Majoros; G Kardos; A Belák; A Maráz; L Asztalos; E Csánky; Z Barta; B Szabó
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

5.  Treatment of invasive candidiasis in the elderly: a review.

Authors:  Aikaterini Flevari; Maria Theodorakopoulou; Aristea Velegraki; Apostolos Armaganidis; George Dimopoulos
Journal:  Clin Interv Aging       Date:  2013-09-09       Impact factor: 4.458
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.